Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
1,000-mile Saharan dust storm, from the sky and from the ground - 2Germany ready to assist Syria's reconstruction, says foreign minister
- 3Which Breakfast Enraptures Your Taste Buds? Vote
- 4Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- 5Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- Israel scales back use of top missile interceptors as Iran barrages persist
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Unsold Rams May Be Less expensive Than You Suspect
- Help Your Efficiency with These Work area Updates
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- NASA releases new photos of interstellar comet 3I/ATLAS
